Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Legend Biotech Corporation - American Depositary Shares (NQ:LEGN)

31.29 -0.78 (-2.42%)
Streaming Delayed Price Updated: 3:23 PM EDT, Oct 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Legend Biotech Corporation - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Amgen Surges on Repatha Expansion, Manufacturing Boost, and Strong Earnings
Thousand Oaks, CA – October 2, 2025 – Amgen (NASDAQ: AMGN) has witnessed a robust surge in its share price, climbing approximately 6% in recent trading sessions, culminating on October 2, 2025, to... 
Via MarketMinute
Topics Economy Intellectual Property Stocks
How Do Investors Really Feel About Legend Biotech?
 
Via Benzinga
Legend Biotech Considering Second Listing Outside US: Report
Via Stocktwits
How Do Investors Really Feel About Legend Biotech?
 
Via Benzinga
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
From Legend Biotech USA Inc.
Via GlobeNewswire
Earnings Outlook For Legend Biotech
 
Via Benzinga
Looking Into Legend Biotech's Recent Short Interest
 
Via Benzinga
Legend Biotech Appoints Carlos Santos as Chief Financial Officer
From Legend Biotech USA Inc.
Via GlobeNewswire
The Analyst Verdict: Legend Biotech In The Eyes Of 5 Experts
 
Via Benzinga
Beyond the Headlines: A Look at Today's Key Corporate Earnings Reports
Today, August 11, 2025, marks a significant day for investors looking beyond the typical S&P 500 giants, as a diverse array of companies across various sectors unveiled their latest quarterly earnings.... 
Via MarketMinute
Topics Economy Stocks
Is Legend Biotech Gaining or Losing Market Support?
 
Via Benzinga
What Does the Market Think About Legend Biotech?
 
Via Benzinga
Legend Biotech Corp. (NASDAQ:LEGN) Reports Mixed Q2 2025 Earnings with Revenue Beat and EPS Miss Amid Strong CARVYKTI Sales
Legend Biotech's Q2 2025 earnings show revenue beat at $255.1M, driven by strong CARVYKTI sales, but EPS missed at -$0.34. Stock rose 1.4% pre-market. 
Via Chartmill
Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
A Glimpse Into The Expert Outlook On Legend Biotech Through 6 Analysts
 
Via Benzinga
Earnings Scheduled For August 11, 2025
 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
From Legend Biotech USA Inc.
Via GlobeNewswire
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results
From Legend Biotech USA Inc.
Via GlobeNewswire
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks. 
Via Benzinga
Topics World Trade
5 Analysts Have This To Say About Legend Biotech
 
Via Benzinga
What Does the Market Think About Legend Biotech?
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.